Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Kedudukan dalam Saham #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Harga Saham
$0.1559364
Disegerakkan terakhir: 2026-09-18
Modal Pasaran
$195.17K
Perubahan (1 hari)
6.60%
Perubahan (1 tahun)
-30.91%
Negara
GB
Perdagangan Fusion Antibodies plc (FAB)

Kategori

Healthcare
Nisbah P/E bagi Fusion Antibodies plc (FAB)
Nisbah P/E pada September 2026 TTM: -6.42
Menurut laporan kewangan dan harga saham terkini Fusion Antibodies plc, nisbah P/E semasa (TTM) ialah -6.42. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak -0.96.
Sejarah nisbah P/E bagi Fusion Antibodies plc dari 2013 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -6.42 86.73%
2025 -3.44 258.24%
2024 -0.96 -75.09%
2023 -3.86 -70.26%
2022 -12.97 -5.91%
2021 -13.79 -54.21%
2020 -30.11 504.68%
2019 -4.98 -79.50%
2018 -24.29 -110.68%
2017 227.44 862.11%
2016 23.64 -107.37%
2015 -320.55 33.40%
2014 -240.30 312.85%
2013 -58.20 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.99 -566.95%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.30 -665.03%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -18.38 186.17%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.34 263.30%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.